Compounded Tirzepatide: Is It Safe, Legal & How Much? (2026)

Compounded tirzepatide is sold at far below the list price of Zepbound and Mounjaro, but compounded drugs are not FDA-approved. Here is what FDA says about safety and compounding limits, and what sellers charge in 2026.

Eduard Cristea
Eduard Cristea
Published: |Updated:
Visit Embodyfrom $49/mo, 12-month plan

Quick Answer: What Is Compounded Tirzepatide?

Compounded tirzepatide is a drug prepared by a compounder and labeled as containing tirzepatide, prescribed via telehealth from about $129/month, versus a list price above $1,000/month for brand Zepbound. Compounded drugs are not FDA-approved, and FDA does not review them for safety, effectiveness or quality before they are marketed. FDA determined the tirzepatide shortage was resolved, and it places limits on compounding, set out below.

From $129/mo (vs $1,000+ brand)Dual GIP + GLP-1 agonistNot FDA-approved (compounded)

What Is Compounded Tirzepatide?

Compounded tirzepatide is prepared by a compounder rather than manufactured by Eli Lilly. Compounded drugs are not FDA-approved.

What makes tirzepatide distinct from semaglutide (the molecule in Ozempic and Wegovy) is its mechanism: tirzepatide is a dual agonist — it activates both the GIP and GLP-1 receptors, whereas semaglutide acts on GLP-1 alone. That dual action is why tirzepatide produced the strongest weight loss of any GLP-1 studied to date: up to roughly 21% average body-weight reduction at the 15mg dose over 72 weeks in the SURMOUNT-1 trial (NEJM, 2022), compared with about 15% for semaglutide 2.4mg in STEP-1 (NEJM, 2021).

Compounded tirzepatide is dispensed as a solution for weekly subcutaneous injection, titrated upward from 2.5mg toward a maintenance dose (typically 5–15mg). Those trial results come from the FDA-approved products and do not establish results for a compounded product.

Is Compounded Tirzepatide Safe?

FDA does not review compounded drugs for safety before they are marketed, so we cannot give you a yes. FDA says compounded drugs should only be used in patients whose medical needs cannot be met by an FDA-approved drug.

As of May 31, 2026, FDA had received more than 730 reports of adverse events associated with compounded tirzepatide, and says it cannot always determine whether the drug caused them. It also lists fraudulent products with false pharmacy names, doses beyond the approved label, and vials used past 28 days. FDA's concerns page. Questions to ask a provider:

  • Which pharmacy or outsourcing facility makes it, and where is it licensed?
  • Does a licensed prescriber review your intake, and can you reach one afterward?
  • Can you see a certificate of analysis for the batch?
  • What are the refund and cancellation terms?

FDA says many adverse events reported for compounded products appear consistent with those of the FDA-approved versions. Talk to your prescriber about side effects and how to measure your dose.

Is Compounded Tirzepatide Legal in 2026?

That depends on who compounds it, for whom, and how. We describe what FDA says and do not say whether any seller's product is lawful.

What FDA says about compounded semaglutide and tirzepatide

FDA and Federal Register pages read November 6, 2026.

  • Not FDA-approved. FDA says compounded drugs are not FDA-approved, which means the agency does not review them for safety, effectiveness or quality before they are marketed. FDA, current as of October 1, 2026.
  • Tirzepatide shortage. FDA determined the tirzepatide injection shortage was resolved on October 2, 2024. After litigation it re-evaluated and issued a new decision on December 19, 2024 that the shortage is resolved. FDA policy page.
  • Semaglutide shortage. FDA determined the semaglutide injection shortage was resolved on February 21, 2025. FDA policy page.
  • End of FDA's grace periods. After district courts denied preliminary injunctions on March 5, 2025 (tirzepatide) and April 24, 2025 (semaglutide), FDA said its period of enforcement discretion for section 503A compounders had ended. FDA policy page.
  • Section 503A (state-licensed pharmacies and physicians). The drug must be compounded for an individual patient based on a prescription, and the compounder may not compound, regularly or in inordinate amounts, drugs that are essentially copies of a commercially available drug. FDA treats a product as essentially a copy unless a prescriber determines and documents a change that produces a significant difference for an identified patient. FDA says it does not intend, at this time, to act on that limit if a compounder fills four or fewer prescriptions of that product in a calendar month. FDA, April 1, 2026 update.
  • Section 503B (outsourcing facilities).Outsourcing facilities are restricted from compounding with bulk drug substances unless the substance is on the 503B bulks list or the drug is on FDA's shortage list. FDA says tirzepatide and semaglutide are on neither. Section 503B also restricts making drugs that are essentially a copy of an FDA-approved drug. FDA policy page.
  • 2026 proposal, not a final decision. On April 30, 2026, FDA proposed to exclude semaglutide, tirzepatide and liraglutide from the 503B bulks list, finding no clinical need. FDA announcement. It later extended the comment period to July 30, 2026. We found no final decision in the Federal Register as of November 6, 2026.

This describes FDA's public statements. It does not say whether any seller's product is lawful, and it is not legal advice. Ask the prescriber or seller which pharmacy makes your medicine and on what basis.

Compounded Tirzepatide vs. Brand Zepbound & Mounjaro

Compounded drugs are not FDA-approved. The differences include FDA review, manufacturer, and price. For weight loss, the relevant brand is Zepbound (FDA-approved tirzepatide for chronic weight management). Mounjaro is the same molecule approved for type 2 diabetes. Both are made by Eli Lilly and carry a retail list price above $1,000/month. Sellers list compounded tirzepatide at $129–$299/month.

Brand Zepbound and Mounjaro went through FDA review for safety, effectiveness and quality. Compounded tirzepatide did not.

Where to Get Compounded Tirzepatide

Listed providers with a recorded tirzepatide price, sorted by that price. We do not independently verify pharmacy licenses. Prices are cash-pay. Compounded drugs are not FDA-approved.

Active listings first, then listings with an inactive link, each by price. A listing held last by publisher decision may follow.

ProviderTirzepatide / moConsultation
EmbodyLowest recorded$129IncludedVisit Embody
CoreAge Rx$129No separate fee stated on its product pagesVisit CoreAge Rx
Sprout Health$199IncludedVisit Sprout Health
Bodybuilding.com Health+$209IncludedVisit BB Health+
ShedRx$225IncludedVisit ShedRx
bmiMD$249IncludedVisit bmiMD
AgelessRx$249FreeVisit AgelessRx
Direct Meds GLP-1$297IncludedVisit Direct Meds

Prices are recorded from each provider's public page and reflect starting rates; see each review for the date. Higher maintenance doses or month-to-month plans may cost more. See our cheapest tirzepatide without insurance guide for the full price breakdown.

What to Check Before You Pay

Ask the provider to confirm that it:

  • Names or discloses its 503A/503B compounding pharmacy on request
  • Requires a real medical intake reviewed by a licensed prescriber — not a 2-minute form
  • Provides a certificate of analysis or third-party testing
  • Does not claim the drug is the same as an FDA-approved drug or a generic, which FDA lists as a warning sign

Use our GLP-1 Scam Checker to vet any provider before you subscribe.

Frequently Asked Questions

What is compounded tirzepatide?

Compounded tirzepatide is prepared by a compounder rather than manufactured by Eli Lilly. It's prescribed via telehealth from about $129/month versus a list price above $1,000/month for brand Zepbound. Compounded drugs are not FDA-approved.

Is compounded tirzepatide safe?

FDA does not review compounded drugs for safety, effectiveness or quality before they are marketed, and it says they should only be used in patients whose medical needs cannot be met by an FDA-approved drug. Talk to your prescriber about your options.

Is compounded tirzepatide legal in 2026?

FDA determined the tirzepatide shortage was resolved on October 2, 2024, and again on December 19, 2024. It says section 503A compounding must be for an individual patient and limits essentially copies, and that tirzepatide is not on the 503B bulks list or the shortage list. We describe FDA's statements and do not say whether any seller's product is lawful. This is not legal advice.

How much does compounded tirzepatide cost?

Compounded tirzepatide starts around $129/month from tracked providers and runs to about $299/month depending on provider, dose, and plan length — versus $1,000+/month for brand Zepbound or Mounjaro at retail.

Is compounded tirzepatide as effective as Zepbound?

We cannot say. Trials such as SURMOUNT-1 studied the FDA-approved product. FDA does not review compounded drugs for effectiveness before they are marketed, and it objects to marketing that describes a compounded drug as matching an approved drug's results.

Embody

from $49/mo, 12-month plan

Visit Embody